Senior Vice President and Head of Global CNS Disease Research at Boehringer Ingelheim, Dr Hugh Marston originally trained in experimental psychopharmacology at the University of Cambridge. After a fellowship at NIDA, he spent 25 years in Scotland, first at the University of Edinburgh, then at Organon Pharmaceuticals as Head of Neurobiology. The Organon neuropsychiatry team, acquired by Schering-Plough then Merck, brought asenapine and sugammadex to market, along with a range of innovative programs into manufacture. He then headed Pharmacology at IOmet Pharma, a micro-pharma company acquired by Merck, having developed clinic-ready packages from scratch. Hugh then headed Translational Neuroscience at Lilly, Erl Wood, before moving to his current role at BI. The BI CNS team, using a circuits-and-systems approach, has an extensive neuropsychiatry pipeline aiming to deliver a new precision in psychiatry. BI’s “breakthrough”-designated iclepertin (GlyT1 inhibitor) is in Phase III for cognitive impairment in schizophrenia. With his long-standing interest in transforming translation from and to the clinic, Hugh has led, from inception, the IMI2 PRISM1 & 2 initiatives seeking transdiagnostic, quantitative biological phenotypes in CNS disorders. He maintains an active interest in academic research through collaborations with UK, European, and US universities and institutions.